Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 7/20 | 0.47 |
| ▸ | EIF4E | P06730 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 4/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 2/20 | 0.37 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25215700 | 0.89 | KMO (0.57) | KMOEIF4ECTSALMNADHODH | |
| SCHEMBL30036507 | 0.83 | KMO (0.47) | KMOEIF4EDHODH | |
| SCHEMBL25551806 | 0.83 | KMO (0.47) | KMOEIF4EDHODH | |
| SCHEMBL25234137 | 0.80 | KMO (0.46) | KMODHODH | |
| SCHEMBL25211353 | 0.79 | KMO (0.56) | KMO | |
| SCHEMBL25245579 | 0.78 | KMO (0.46) | KMODHODH | |
| SCHEMBL25551841 | 0.78 | KMO (0.57) | KMOLMNA | |
| SCHEMBL25242428 | 0.78 | KMO (0.51) | KMOEIF4ECTSACCNE1CDK2 | |
| SCHEMBL25566923 | 0.77 | HTR5A (0.51) | KMOCDK2HTR5A | |
| SCHEMBL25211840 | 0.77 | KMO (0.43) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | KMO 3071/4885EIF4E 1979/4885CTSA 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.